Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2002
Business Overview: BD operates through three primary segments: BD Medical Systems, BD Clinical Laboratory Solutions, and BD Biosciences. The company manufactures and distributes medical devices, diagnostic systems, and life science products globally.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2002 | Q3 2001 | 9 Months 2002 | 9 Months 2001 |
|---|---|---|---|---|
| Revenues | $998.5 | $943.3 | $2,956.4 | $2,758.7 |
| Operating Income | $165.9 | $166.6 | $483.5 | $456.9 |
| Net Income | $119.7 | $118.1 | $348.6 | $269.2 |
| Diluted EPS | $0.44 | $0.44 | $1.29 | $1.00 |
| Operating Cash Flow (9mo) | $532.4 (2002) vs $524.5 (2001) | |||
| Free Cash Flow (9mo) | $269.4 (2002) vs $258.6 (2001) | |||
| Total Debt | $1.25 billion (Short-term: $471M, Long-term: $782M) | |||
| Cash & Equivalents | $176.0 million | |||
| Gross Margin | 48.5% | 49.7% | 48.0% | 48.7% |
| Operating Margin | 16.6% | 17.7% | 16.4% | 16.6% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 6% in Q3 and 7% for the nine months. International revenue grew 9% excluding unfavorable foreign currency impacts. Growth was driven by safety-engineered devices and prefillable drug delivery systems, partially offset by lower sales of conventional devices and insulin syringes due to accounting changes (SAB 101).
- Profitability: Net income rose 1.3% in Q3 and 29.5% for the nine months. The nine-month increase was significantly aided by the adoption of SFAS 142 (Goodwill), which eliminated goodwill amortization, providing a $7.50 per share benefit over the period.
- Special Charges: The company recorded $11.6 million in special charges for Q3 and $21.5 million for the nine months, primarily related to a manufacturing restructuring in the Medical segment (severance and asset write-downs). This was partially offset by a $4.2 million reversal of prior fiscal year charges.
- Segment Performance:
- Medical: Revenues up 7% (Q3). Growth driven by safety devices and prefillable syringes; offset by lower consumer healthcare sales.
- Clinical Lab: Revenues up 5% (Q3). Growth driven by preanalytical solutions; offset by distributor inventory stocking issues.
- Biosciences: Revenues up 3% (Q3). Growth in immunology/cell biology reagents offset by flat flow cytometry sales and an 8% decline in molecular biology reagents.
Guidance, Outlook, and Risks
- Restructuring Outlook: The current Medical segment restructuring is expected to result in net savings of approximately $2 million per quarter beginning in Q3 of fiscal 2003. Prior restructuring plans (2000 and 1998) are expected to yield annual savings of $30 million and $4 million, respectively.
- Capital Allocation: The company repurchased 4.9 million shares for $174 million in the first nine months. Capital expenditures for fiscal 2002 are not expected to exceed $300 million.
- Potential Divestiture: BD entered a non-binding letter of intent to sell its critical care product line to AorTech International plc. If consummated, the company expects to record a pre-tax loss of $35 million to $40 million. The transaction is subject to significant uncertainty.
- Investment Impairment Risk: An equity investment with a carrying value of $15 million has traded below cost since January 2002. As of July 31, 2002, the cumulative unrealized loss was approximately $10 million. Management is evaluating whether to write down the asset in Q4 2002.
- Legal Contingencies: Significant litigation includes antitrust claims by Retractable Technologies, Inc. (trial scheduled for Jan 2003) and class action lawsuits regarding needlestick injuries. Management does not expect these to have a material adverse effect on financial condition but notes potential for future charges.
Investor Verification Checklist
- Accounting Changes: Verify the impact of SFAS 142 (elimination of goodwill amortization) on year-over-year earnings comparisons.
- Revenue Recognition: Confirm the impact of SAB 101 adoption on insulin syringe revenue recognition and the reliance on distributor sell-through data.
- Restructuring Costs: Monitor the execution of the Medical segment restructuring and the realization of projected $2 million quarterly savings starting in fiscal 2003.
- Divestiture Status: Track the progress of the critical care product line sale to AorTech and the potential $35-$40 million loss recognition.
- Investment Valuation: Watch for a potential Q4 2002 write-down of the $15 million equity investment currently showing a $10 million unrealized loss.
- Legal Exposure: Review updates on the RTI antitrust litigation and needlestick class action certifications.